GSK

Debut of GSK consumer-health spin-off Haleon disappoints

Debut of GSK consumer-health spin-off Haleon disappoints

GSK’s spin-off of its consumer health division, the largest London listing in more than a decade, made a lacklustre debut on Monday as the group now called Haleon launched into choppy markets overshadowed by inflation concerns. Shares in Haleon dropped 6.6 per cent on Monday to 308.4p after opening at 330p, giving the owner of …

Debut of GSK consumer-health spin-off Haleon disappoints Read More »

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK

For investors and media only Issued: 10 June 2022, London UK – LSE announcement First RSV vaccine candidate to show statistically significant and clinically meaningful efficacy in adults aged 60 years and above The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years …

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults | GSK Read More »